Compare LYEL & OBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LYEL | OBT |
|---|---|---|
| Founded | 2018 | 1892 |
| Country | United States | United States |
| Employees | 161 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 556.1M | 463.8M |
| IPO Year | 2021 | 2021 |
| Metric | LYEL | OBT |
|---|---|---|
| Price | $23.47 | $35.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | $30.60 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 74.3K | 70.4K |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.05% |
| EPS Growth | N/A | ★ 34.82 |
| EPS | N/A | ★ 3.33 |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | $14.27 |
| Revenue Next Year | $16,285.34 | $7.99 |
| P/E Ratio | ★ N/A | $10.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $21.11 |
| 52 Week High | $45.00 | $37.99 |
| Indicator | LYEL | OBT |
|---|---|---|
| Relative Strength Index (RSI) | 55.08 | 69.56 |
| Support Level | $21.27 | $29.62 |
| Resistance Level | $27.30 | $37.99 |
| Average True Range (ATR) | 1.71 | 1.05 |
| MACD | 0.43 | 0.29 |
| Stochastic Oscillator | 74.68 | 92.66 |
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Orange County Bancorp Inc is a community bank holding company providing commercial and consumer banking services to individuals, small businesses, and local governments. It operates through two segments: Banking and Wealth Management. The Banking segment, the primary revenue driver, offers loans such as commercial real estate, construction, commercial & industrial, multifamily, and residential mortgages, along with services like cash management, escrow, deposits, ATMs, and digital banking. The Wealth Management segment provides investment management, trust services (trustee, administrator, custodian), and financial planning and advisory services to individuals and institutions.